Lorazepam%2525252525252525252525252525252525252525252525252525252525252520%2525252525252525252525252525252525252525252525252525252525252528representative%2525252525252525252525252525252525252525252525252525252525252520benzodiazepine%2525252525252525252525252525252525252525252525252525252525252529

# Lorazepam (representative benzodiazepine) ## Overview Lorazepam is an intermediate-acting benzodiazepine that enhances **GABA-A receptor** activity. It provides anxiolytic, sedative-hypnotic, anticonvulsant, and muscle-relaxant effects. - **Routes:** oral, IV, IM - **Approximate half-life:** 10–20 hours; may be prolonged in older adults or organ dysfunction - **Controlled substance:** Schedule IV in the United States - **Boxed warning:** Concomitant use with opioids can cause profound sedation, respiratory depression, coma, and death. ## Primary Indications - Anxiety disorders and short-term relief of severe anxiety - Insomnia related to anxiety or transient situational stress - Status epilepticus - Preanesthetic medication/procedural anxiolysis - **Off-label:** alcohol withdrawal, catatonia, chemotherapy-related anticipatory nausea, and severe agitation ## Adult Dosing ### Anxiety - **Oral:** 2–3 mg/day divided into 2–3 doses - Usual range: **2–6 mg/day** in divided doses - Maximum commonly cited: **10 mg/day**, although lower maximums may apply by local protocol - Older or debilitated adults: start **0.5–1 mg once or twice daily**; titrate cautiously ### Insomnia associated with anxiety - **Oral:** 2–4 mg at bedtime - Older or debilitated adults: start **0.5–1 mg at bedtime** ### Status epilepticus - **IV:** 0.1 mg/kg, usually **4 mg IV once**; maximum **4 mg per dose** - May repeat once after **5–15 minutes** if seizures persist or recur - Common adult maximum: **8 mg total** for an episode; follow the institutional status epilepticus protocol - Administer IV slowly, generally no faster than **2 mg/minute** - Ensure airway and ventilatory support are immediately available ### Preanesthetic medication - **IM or IV:** commonly **0.044 mg/kg**, up to **2 mg**; some protocols use up to **0.05 mg/kg**, maximum **4 mg** - Timing and route depend on the procedure and local anesthesia protocol - IV doses must be diluted and administered slowly according to the product labeling ### Alcohol withdrawal — off-label - Regimens vary substantially. A common approach is **1–2 mg PO/IV every 6–8 hours**, with additional symptom-triggered doses as needed. - Use a validated withdrawal scale and institutional protocol; monitor closely for respiratory depression and oversedation. ## Pediatric Dosing ### Status epilepticus - **IV:** 0.1 mg/kg per dose, maximum **4 mg per dose** - May repeat once after approximately **5–15 minutes** if needed - Use local pediatric status epilepticus guidance; respiratory support must be available - Buccal or intranasal lorazepam is not interchangeable with IV dosing and is not routinely standardized ### Preprocedural anxiolysis/premedication - **Oral or IM:** approximately **0.05 mg/kg**, maximum **2 mg** in many pediatric protocols - Pediatric labeling and institutional practice vary by age, formulation, and procedure ### Anxiety or insomnia - Routine oral treatment is **not well established in children**, particularly in children younger than 12 years. Use only with specialist oversight. ### Neonates and young infants - Avoid routine use unless specifically directed by a neonatal or pediatric specialist. Risks include respiratory depression, paradoxical agitation, prolonged sedation, and formulation-related excipient toxicity. ## Dose Adjustments ### Older adults or frail patients - Start at approximately **25–50% of the usual adult dose** - Titrate slowly; avoid routine escalation to high doses ### Renal impairment - Lorazepam is glucuronidated, but its inactive glucuronide metabolite can accumulate in renal impairment. - For intermittent oral use, no universally accepted adjustment exists; use a lower dose and monitor closely. - Avoid prolonged or high-dose IV therapy when possible, particularly in severe renal impairment, because **propylene glycol toxicity** may occur with some injectable formulations. ### Hepatic impairment - Severe hepatic impairment may reduce clearance. - Start low and titrate slowly; avoid high or frequent dosing. - Lorazepam may be preferred over many hepatically oxidized benzodiazepines, but it is not risk-free. ### Concomitant valproate or probenecid - Consider reducing lorazepam dose by approximately **50%**: - Valproate can increase lorazepam exposure. - Probenecid can substantially prolong lorazepam elimination. ## Contraindications - Hypersensitivity to lorazepam or other benzodiazepines - **Acute narrow-angle glaucoma** - Intra-arterial administration of injectable lorazepam - Formulation-specific contraindications, including sensitivity to excipients Use extreme caution or avoid when possible in: - Severe respiratory insufficiency, untreated obstructive sleep apnea, or myasthenia gravis - Severe hepatic or renal dysfunction - Pregnancy, especially prolonged use or near delivery - History of substance use disorder - Older adults at high risk for falls or delirium ## Adverse Effects ### Common - Drowsiness, sedation, fatigue - Dizziness, ataxia, impaired coordination - Confusion, memory impairment, slowed reaction time - Muscle weakness - Nausea or constipation ### Serious - Respiratory depression, apnea, hypotension, coma - Falls and fractures - Delirium or paradoxical agitation, especially in children and older adults - Dependence, misuse, and overdose - Withdrawal symptoms, including anxiety, insomnia, tremor, delirium, and seizures - Rare: severe allergic reactions ### Injectable formulation-specific concerns - Pain or phlebitis - Hypotension - **Propylene glycol toxicity** with repeated or high-dose IV administration: metabolic acidosis, hyperosmolarity, renal dysfunction, and hypotension ## Key Drug Interactions - **Opioids:** markedly increased risk of sedation, respiratory depression, coma, and death. Use only when alternatives are inadequate; use the lowest effective doses and monitor closely. - **Alcohol, sedating antihistamines, antipsychotics, sedating antidepressants, gabapentinoids, muscle relaxants, and anesthetics:** additive CNS and respiratory depression. - **Valproate:** increased lorazepam exposure; consider approximately 50% dose reduction. - **Probenecid:** increased exposure and prolonged effect; consider approximately 50% dose reduction. - **Other benzodiazepines or sedative-hypnotics:** additive sedation and impairment. - Lorazepam undergoes glucuronidation and has fewer clinically important CYP-mediated interactions than diazepam or midazolam; additive pharmacodynamic effects remain clinically important. ## Monitoring - Respiratory rate, oxygen saturation, level of consciousness, and airway status—especially with IV dosing or concurrent opioids - Blood pressure and heart rate after parenteral administration - Sedation, gait, falls, cognition, and paradoxical agitation - Seizure control and recurrence in status epilepticus - Signs of misuse, tolerance, dependence, and withdrawal - Renal function and acid–base status during prolonged or high-dose IV therapy - Reassess ongoing need frequently; use the shortest effective duration ## Clinical Pearls - Benzodiazepines should generally be used for the **shortest practical duration**, commonly no longer than 2–4 weeks for anxiety or insomnia unless a specialist provides a longer-term plan. - Do not stop chronic therapy abruptly. Taper gradually; the schedule depends on dose, duration, and withdrawal risk. - Oral, IM, and IV doses are **not automatically interchangeable**. - For status epilepticus, do not delay benzodiazepine treatment while awaiting laboratory or imaging results; simultaneously prepare definitive antiseizure therapy and airway support. - Flumazenil can precipitate seizures and acute withdrawal, particularly in chronic benzodiazepine users or mixed overdoses; it is not routinely used for undifferentiated overdose. - Lorazepam may cause paradoxical disinhibition or agitation; avoid escalating repeatedly without reassessing the diagnosis and safety risks. - Avoid driving, operating machinery, and alcohol while taking lorazepam. - Injectable products and dilution, maximum infusion rate, preservatives, and excipients vary by manufacturer; verify the specific product. > **Educational disclaimer:** This summary is for educational use and does not replace patient-specific assessment, institutional protocols, or current product labeling. Verify current prescribing information, formulation-specific instructions, and local pediatric/status epilepticus protocols before prescribing or administering lorazepam.